Mizuho Initiates Coverage on Senseonics (NYSE:SENS)

Investment analysts at Mizuho assumed coverage on shares of Senseonics (NYSE:SENS) in a report released on Thursday, MarketBeat reports. The brokerage set an “outperform” rating and a $2.00 price target on the stock. Mizuho’s price target points to a potential upside of 234.06% from the stock’s previous close.

Several other equities research analysts have also issued reports on SENS. StockNews.com started coverage on Senseonics in a report on Thursday, December 26th. They set a “sell” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Senseonics in a research note on Wednesday, March 5th.

Senseonics Trading Up 4.9 %

Shares of NYSE SENS opened at $0.60 on Thursday. The firm has a market capitalization of $390.26 million, a PE ratio of -4.61 and a beta of 0.84. Senseonics has a one year low of $0.25 and a one year high of $1.40. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. The business has a 50-day moving average price of $0.78 and a two-hundred day moving average price of $0.58.

Senseonics (NYSE:SENS) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.09). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. During the same quarter in the previous year, the company earned ($0.07) EPS. As a group, analysts predict that Senseonics will post -0.14 earnings per share for the current fiscal year.

Institutional Trading of Senseonics

Several large investors have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new position in Senseonics during the 4th quarter worth $26,000. HighTower Advisors LLC bought a new position in Senseonics in the 4th quarter worth approximately $32,000. Two Sigma Investments LP acquired a new position in shares of Senseonics during the fourth quarter worth approximately $36,000. FMR LLC boosted its position in shares of Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after acquiring an additional 167,970 shares during the period. Finally, Ridgecrest Wealth Partners LLC acquired a new stake in shares of Senseonics in the fourth quarter worth $60,000. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.